Skip to main content
. 2024 Mar 19;84(11):1898–1914. doi: 10.1158/0008-5472.CAN-23-2957

Figure 6.

Figure 6. Prediction of lung cancer using immune hypoM in blood and proximal epithelial hyperM in buccal samples compared with previously described predictors. A, Comparison of the AUCs of AHRR (cg05575921), F2RL3 (cg03636183), and mean methylation at immune hypoM to identify any lung cancer cases within 17 years in 259 current smokers in the ESTHER study. B, Comparison of the AUCs of AHRR (cg05575921), F2RL3 (cg03636183), and mean methylation at immune hypoM (corrected for immune cell proportion) to identify any lung or airway cancer cases within 22 years in 31 blood samples (n = 6 cancer cases) of the validation set (same individuals as in C). C, Comparison of the AUCs of AHRR (cg05575921), F2RL3 (cg03636183), and mean methylation at proximal epithelial hyperM (corrected for immune cell proportion) to identify any lung or airway cancer cases within 22 years in 31 buccal samples (n = 6 cancer cases) of the validation set (same individuals as in B).

Prediction of lung cancer using immune hypoM in blood and proximal epithelial hyperM in buccal samples compared with previously described predictors. A, Comparison of the AUCs of AHRR (cg05575921), F2RL3 (cg03636183), and mean methylation at immune hypoM to identify any lung cancer cases within 17 years in 259 current smokers in the ESTHER study. B, Comparison of the AUCs of AHRR (cg05575921), F2RL3 (cg03636183), and mean methylation at immune hypoM (corrected for immune cell proportion) to identify any lung or airway cancer cases within 22 years in 31 blood samples (n = 6 cancer cases) of the validation set (same individuals as in C). C, Comparison of the AUCs of AHRR (cg05575921), F2RL3 (cg03636183), and mean methylation at proximal epithelial hyperM (corrected for immune cell proportion) to identify any lung or airway cancer cases within 22 years in 31 buccal samples (n = 6 cancer cases) of the validation set (same individuals as in B).